QUARTERLY REPORT

Q2 2026 — Form 10-Q

Q2 2026PDF · 43 pages427 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 27, 2026 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 	04-2209186
(State or other jurisdiction of incorporation or organization) 	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $1.00 par value 	TMO 	New York Stock Exchange
1.450% Notes due 2027 	TMO 27 	New York Stock Exchange
1.750% Notes due 2027 	TMO 27B 	New York Stock Exchange
Floating Rate Notes due 2027 	TMO 27D 	New York Stock Exchange
0.500% Notes due 2028 	TMO 28A 	New York Stock Exchange
1.375% Notes due 2028 	TMO 28 	New York Stock Exchange
1.950% Notes due 2029 	TMO 29 	New York Stock Exchange
0.875% Notes due 2031 	TMO 31 	New York Stock Exchange
2.375% Notes due 2032 	TMO 32 	New York Stock Exchange
3.650% Notes due 2034 	TMO 34 	New York Stock Exchange
3.628% Notes due 2035 	TMO 35A 	New York Stock Exchange
2.875% Notes due 2037 	TMO 37 	New York Stock Exchange
1.500% Notes due 2039 	TMO 39 	New York Stock Exchange
1.875% Notes due 2049 	TMO 49 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer ☒ 	Accelerated filer ☐ 	Non-accelerated filer ☐
Smaller reporting company ☐ 	Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 27, 2026, the Registrant had 369,747,286 shares of Common Stock outstanding.

-- 1 of 43 --

THERMO FISHER SCIENTIFIC INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED JUNE 27, 2026
TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION
Item 1. 	Financial Statements (Unaudited) 	3
Condensed Consolidated Balance Sheets 	3
Condensed Consolidated Statements of Income 	4
Condensed Consolidated Statements of Comprehensive Income 	5
Condensed Consolidated Statements of Cash Flows 	6
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity 	7
Notes to Condensed Consolidated Financial Statements 	9
Note 1. Nature of Operations and Summary of Significant Accounting Policies 	9
Note 2. Supplemental Balance Sheet Information 	10
Note 3. Debt and Other Financing Arrangements 	11
Note 4. Fair Value Measurements 	14
Note 5. Commitments and Contingencies 	15
Note 6. Supplemental Income Statement Information 	16
Note 7. Income Taxes 	18
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity 	19
Note 9. Supplemental Cash Flow Information 	20
Note 10. Derivatives 	20
Note 11. Business Segment Information 	21
Note 12. Acquisitions and Divestiture 	26
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	28
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	36
Item 4. 	Controls and Procedures 	36
PART II - OTHER INFORMATION
Item 1. 	Legal Proceedings 	37
Item 1A. 	Risk Factors 	37
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	37
Item 5. 	Other Information 	37
Item 6. 	Exhibits 	38
2

-- 2 of 43 --

THERMO FISHER SCIENTIFIC INC.
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 27, 	December 31,
(In millions except share and per share amounts) 	2026 	2025
Assets
Current assets:
Cash and cash equivalents 	$ 	4,064 	$ 	9,852
Short-term investments 	— 	253
Accounts receivable, less allowances of $148 and $147 	9,451 	8,900
Inventories 	5,627 	5,425
Contract assets, net 	1,688 	1,666
Other current assets 	2,536 	2,612
Total current assets 	23,365 	28,707
Property, plant and equipment, net 	10,755 	10,565
Acquisition-related intangible assets, net 	18,606 	15,838
Other assets 	5,616 	5,871
Goodwill 	54,832 	49,362
Total assets 	$ 	113,174 	$ 	110,343
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations 	$ 	3,368 	$ 	3,533
Accounts payable 	3,268 	3,622
Accrued payroll and employee benefits 	1,694 	1,995
Contract liabilities 	2,918 	2,710
Other accrued expenses 	3,823 	3,329
Total current liabilities 	15,069 	15,189
Deferred income taxes 	1,579 	1,493
Other long-term liabilities 	4,538 	4,273
Long-term obligations 	39,181 	35,852
Redeemable noncontrolling interest 	121 	122
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued 	— 	—
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,673,899 and 445,160,301 shares issued 	446 	445
Capital in excess of par value 	18,870 	18,563
Retained earnings 	62,194 	59,156
Treasury stock at cost, 75,926,613 and 68,938,831 shares 	(26,370) 	(22,309)
Accumulated other comprehensive income/(loss) 	(2,460) 	(2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity 	52,679 	53,407
Noncontrolling interests 	7 	7
Total equity 	52,686 	53,415
Total liabilities, redeemable noncontrolling interest and equity 	$ 	113,174 	$ 	110,343
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

-- 3 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(In millions except per share amounts) 	2026 	2025 	2026 	2025
Revenues
Product revenues 	$ 	6,823 $ 	6,249 $ 	13,100 $ 	12,229
Service revenues 	5,171 	4,605 	9,899 	8,990
Total revenues 	11,994 	10,855 	22,999 	21,219
Costs and operating expenses:
Cost of product revenues 	3,462 	3,239 	6,723 	6,364
Cost of service revenues 	3,650 	3,207 	6,964 	6,212
Selling, general and administrative expenses 	2,333 	2,140 	4,514 	4,218
Research and development expenses 	364 	352 	700 	695
Restructuring and other costs 	98 	82 	147 	180
Total costs and operating expenses 	9,907 	9,021 	19,049 	17,668
Operating income 	2,087 	1,834 	3,950 	3,551
Interest income 	207 	297 	440 	501
Interest expense 	(401) 	(404) 	(755) 	(707)
Other income/(expense) 	31 	(19) 	22 	(16)
Income before income taxes 	1,924 	1,709 	3,658 	3,329
Benefit from/(provision for) income taxes 	(167) 	(92) 	(238) 	(187)
Equity in earnings/(losses) of unconsolidated entities 	(15) 	2 	(23) 	(12)
Net income 	1,741 	1,618 	3,397 	3,130
Less: net income/(loss) attributable to noncontrolling interests and redeemable
noncontrolling interest 	5 	2 	10 	6
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,736 $ 	1,617 $ 	3,387 $ 	3,124
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic 	$ 	4.68 $ 	4.28 $ 	9.11 $ 	8.27
Diluted 	$ 	4.68 $ 	4.28 $ 	9.10 $ 	8.26
Weighted average shares
Basic 	371 	378 	372 	378
Diluted 	371 	378 	372 	378
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

-- 4 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(In millions) 	2026 	2025 	2026 	2025
Comprehensive income/(loss)
Net income 	$ 	1,741 	1,618 $ 	3,397 $ 	3,130
Other comprehensive income/(loss):
Cumulative translation adjustment:
Cumulative translation adjustment (net of tax provision (benefit) of $(41),
$(207), $(14), and $(414)) 	39 	(447) 	(19) 	(87)
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax
(provision) benefit of $0, $0, $0, and $0) 	1 	1 	1 	1
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the
period (net of tax (provision) benefit of $0, $3, $(1), and $4) 	— 	(8) 	2 	(11)
Amortization of net loss included in net periodic pension cost (net of tax
(provision) benefit of $0, $1, $1 and $1) 	1 	3 	2 	4
Total other comprehensive income/(loss) 	41 	(451) 	(14) 	(93)
Comprehensive income/(loss) 	1,782 	1,168 	3,383 	3,037
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable
noncontrolling interest 	9 	4 	8 	12
Comprehensive income attributable to Thermo Fisher Scientific Inc. 	$ 	1,773 $ 	1,164 $ 	3,375 $ 	3,025
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

-- 5 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six months ended
June 27, 	June 28,
(In millions) 	2026 	2025
Operating activities
Net income 	$ 	3,397 	$ 	3,130
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 	638 	532
Amortization of acquisition-related intangible assets 	915 	859
Change in deferred income taxes 	(466) 	(601)
Stock-based compensation 	165 	156
Other net non-cash expenses 	205 	198
Changes in assets and liabilities, excluding the effects of acquisitions 	(1,537) 	(2,151)
Net cash provided by operating activities 	3,317 	2,122
Investing activities
Purchases of property, plant and equipment 	(826) 	(656)
Proceeds from sale of property, plant and equipment 	13 	13
Proceeds from cross-currency interest rate swap interest settlements 	187 	134
Acquisitions, net of cash acquired 	(8,872) 	—
Purchases of investments 	(35) 	(311)
Proceeds from sales and maturities of investments 	253 	6
Net proceeds from terminations of cross-currency interest rate swaps 	481 	—
Other investing activities, net 	1 	—
Net cash used in investing activities 	(8,797) 	(815)
Financing activities
Net proceeds from issuance of debt 	5,238 	2,840
Repayment of debt 	(1,412) 	(1,625)
Proceeds from issuance of commercial paper 	389 	—
Repayments of commercial paper 	(389) 	—
Purchases of company common stock 	(4,000) 	(2,000)
Dividends paid 	(337) 	(311)
Other financing activities, net 	33 	3
Net cash used in financing activities 	(478) 	(1,093)
Exchange rate effect on cash 	176 	348
Increase/(decrease) in cash, cash equivalents and restricted cash 	(5,782) 	563
Cash, cash equivalents and restricted cash at beginning of period 	9,879 	4,040
Cash, cash equivalents and restricted cash at end of period 	$ 	4,096 	$ 	4,603
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

-- 6 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Three months ended June 27, 2026
Balance at March 28, 2026 	$ 	121 	445 $ 	445 $ 18,713 $ 60,632 	74 $ (25,360) $ 	(2,497) $ 	51,934 $ 	7 $ 51,940
Issuance of shares under stock
plans 	— 	— 	— 	75 	— 	— 	(1) 	— 	74 	— 	74
Stock-based compensation 	— 	— 	— 	82 	— 	— 	— 	— 	82 	— 	82
Purchases of company common
stock 	— 	— 	— 	— 	— 	2 	(1,000) 	— 	(1,000) 	— 	(1,000)
Dividends declared ($0.47 per
share) 	— 	— 	— 	— 	(174) 	— 	— 	— 	(174) 	— 	(174)
Net income/(loss) 	4 	— 	— 	— 	1,736 	— 	— 	— 	1,736 	1 	1,737
Other comprehensive
income/(loss) 	4 	— 	— 	— 	— 	— 	— 	37 	37 	— 	37
Contributions from (distributions
to) noncontrolling interests 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(9) 	— 	(9) 	— 	(9)
Balance at June 27, 2026 	$ 	121 	446 $ 	446 $ 18,870 $ 62,194 	76 $ (26,370) $ 	(2,460) $ 	52,679 $ 	7 $ 52,686
Three months ended June 28, 2025
Balance at March 29, 2025 	$ 	128 	444 $ 	444 $ 18,111 $ 54,447 	67 $ (21,269) $ 	(2,343) $ 	49,390 $ 	(33) $ 49,357
Issuance of shares under stock
plans 	— 	— 	— 	41 	— 	— 	(1) 	— 	40 	— 	40
Stock-based compensation 	— 	— 	— 	81 	— 	— 	— 	— 	81 	— 	81
Dividends declared ($0.43 per
share) 	— 	— 	— 	— 	(163) 	— 	— 	— 	(163) 	— 	(163)
Net income/(loss) 	3 	— 	— 	— 	1,617 	— 	— 	— 	1,617 	(2) 	1,615
Other comprehensive
income/(loss) 	3 	— 	— 	— 	— 	— 	— 	(453) 	(453) 	— 	(454)
Contributions from (distributions
to) noncontrolling interests 	(8) 	— 	— 	— 	— 	— 	— 	— 	— 	— 	—
Balance at June 28, 2025 	$ 	126 	444 $ 	444 $ 18,232 $ 55,901 	67 $ (21,269) $ 	(2,797) $ 	50,512 $ 	(35) $ 50,476
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

-- 7 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Continued)
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Six months ended June 27, 2026
Balance at December 31, 2025 	$ 	122 	445 $ 	445 $ 18,563 $ 59,156 	69 $ (22,309) $ 	(2,448) $ 	53,407 $ 	7 $ 53,415
Issuance of shares under stock
plans 	— 	1 	1 	142 	— 	— 	(24) 	— 	118 	— 	118
Stock-based compensation 	— 	— 	— 	165 	— 	— 	— 	— 	165 	— 	165
Purchases of company common
stock 	— 	— 	— 	— 	— 	7 	(4,000) 	— 	(4,000) 	— 	(4,000)
Dividends declared ($0.94 per
share) 	— 	— 	— 	— 	(349) 	— 	— 	— 	(349) 	— 	(349)
Net income/(loss) 	9 	— 	— 	— 	3,387 	— 	— 	— 	3,387 	1 	3,388
Other comprehensive
income/(loss) 	(2) 	— 	— 	— 	— 	— 	— 	(12) 	(12) 	— 	(12)
Contributions from (distributions
to) noncontrolling interests 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(38) 	— 	(38) 	— 	(38)
Balance at June 27, 2026 	$ 	121 	446 $ 	446 $ 18,870 $ 62,194 	76 $ (26,370) $ 	(2,460) $ 	52,679 $ 	7 $ 52,686
Six months ended June 28, 2025
Balance at December 31, 2024 	$ 	120 	444 $ 	444 $ 17,962 $ 53,102 	63 $ (19,226) $ 	(2,697) $ 	49,584 $ 	(33) $ 49,551
Issuance of shares under stock
plans 	— 	1 	1 	115 	— 	— 	(26) 	— 	90 	— 	90
Stock-based compensation 	— 	— 	— 	156 	— 	— 	— 	— 	156 	— 	156
Purchases of company common
stock 	— 	— 	— 	— 	— 	4 	(2,000) 	— 	(2,000) 	— 	(2,000)
Dividends declared ($0.86 per
share) 	— 	— 	— 	— 	(325) 	— 	— 	— 	(325) 	— 	(325)
Net income/(loss) 	8 	— 	— 	— 	3,124 	— 	— 	— 	3,124 	(2) 	3,122
Other comprehensive
income/(loss) 	6 	— 	— 	— 	— 	— 	— 	(99) 	(99) 	— 	(99)
Contributions from (distributions
to) noncontrolling interests 	(8) 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(17) 	— 	(17) 	— 	(17)
Balance at June 28, 2025 	$ 	126 	444 $ 	444 $ 18,232 $ 55,901 	67 $ (21,269) $ 	(2,797) $ 	50,512 $ 	(35) $ 50,476
The accompanying notes are an integral part of these condensed consolidated financial statements.
8

-- 8 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life
sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and
manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare
and diagnostics.
Interim Financial Statements
The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management,
reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at June 27, 2026, the results of operations for the three-
and six-month periods ended June 27, 2026 and June 28, 2025, and the cash flows for the six-month periods ended June 27, 2026 and June 28, 2025. Interim results
are not necessarily indicative of results for a full year.
The condensed consolidated balance sheet presented as of December 31, 2025, has been derived from the audited consolidated financial statements as of that date.
The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the
annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in
conjunction with the 2025 financial statements and notes included in the company’s Annual Report on Form 10-K. Certain reclassifications of prior year amounts
have been made to conform to the current year presentation.
Note 1 to the consolidated financial statements for 2025 describes the significant accounting estimates and policies used in preparation of the consolidated financial
statements. There have been no material changes in the company’s significant accounting policies during the six months ended June 27, 2026.
Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts.
As a result, the sum of components may not equal corresponding totals due to rounding.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and
businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on
the company's financial statements or disclosures.
Standard 	Description 	Adoption timing and approach
Impact of adoption or
other significant
matters
Standards recently adopted
ASU No. 2023-09, Income Taxes (Topic
740): Improvements to Income Tax
Disclosures
Among other things, new guidance to disclose additional
information about the tax rate reconciliation and income taxes
paid.
2025 annual report and interim periods
thereafter using a prospective method. Increased annual
disclosures in Notes 7
and 9
Standards not yet adopted
ASU No. 2024-03, Income Statement–
Reporting Comprehensive Income–Expense
Disaggregation Disclosures (Subtopic 220-
40): Disaggregation of Income Statement
Expenses
New guidance to disclose specified information about certain
costs and expenses. 2027 annual report and interim periods
thereafter using a prospective or
retrospective method.
Will increase
disclosures in Note 6
9

-- 9 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Standard 	Description 	Adoption timing and approach
Impact of adoption or
other significant
matters
ASU No. 2025-06, Intangibles–Goodwill
and Other–Internal-Use Software (Subtopic
350-40): Targeted Improvements to the
Accounting for Internal-Use Software
Among other things, new guidance to modernize the accounting
for costs to develop software for internal use.
2028 annual report and interim periods
thereafter using a prospective,
retrospective, or modified transition
method; early adoption is permitted.
Currently evaluating
adoption impact,
timing, and method
ASU No. 2025-10, Government Grants
(Topic 832): Accounting for Government
Grants Received by Business Entities
Among other things, establishes guidance for the recognition,
measurement, and presentation of government grants.
2029 using a retrospective, modified
retrospective, or modified prospective
approach; early adoption is permitted.
Currently evaluating
adoption impact,
timing, and method
Note 2. Supplemental Balance Sheet Information
Inventories
The components of inventories are as follows:
(In millions) 	June 27, 2026 	December 31, 2025
Raw materials 	$ 	1,991 	$ 	1,877
Work in process 	952 	889
Finished goods 	2,683 	2,659
Inventories 	$ 	5,627 	$ 	5,425
Contract-related Balances
Contract asset and liability balances are as follows:
(In millions) 	June 27, 2026 	December 31, 2025
Current contract assets, net 	$ 	1,688 	$ 	1,666
Noncurrent contract assets, net 	— 	1
Current contract liabilities 	2,918 	2,710
Noncurrent contract liabilities 	1,043 	1,183
In the three- and six-month periods ended June 27, 2026, the company recognized revenues of $0.71 billion and $2.00 billion, respectively, that were included in the
contract liabilities balance at December 31, 2025. In the three- and six-month periods ended June 28, 2025, the company recognized revenues of $0.73 billion and
$2.09 billion, respectively, that were included in the contract liabilities balance at December 31, 2024.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 27, 2026, was $29.70
billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 52% of which is expected to occur within the
next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements,
which typically have durations of three to five years.
10

-- 10 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 3. Debt and Other Financing Arrangements
The company’s debt and other financing arrangements are as follows:
Effective interest rate at
June 27, 	June 27, 	December 31,
(Dollars in millions) 	2026 	2026 	2025
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 	$ 	— 	$ 	587
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 	— 	822
4.953% 3-Year Senior Notes, Due 8/10/2026 	5.07 % 	600 	600
0.832% 1.5-Year Senior Notes, Due 9/7/2026 (Swiss franc-denominated) 	1.12 % 	506 	517
5.00% 3-Year Senior Notes, Due 12/5/2026 	5.24 % 	1,000 	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 	1.65 % 	569 	587
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 	1.97 % 	683 	705
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 	1.18 % 	179 	184
4.80% 5-Year Senior Notes, Due 11/21/2027 	5.00 % 	600 	600
Floating Rate (EURIBOR + 0.280%) 2-Year Senior Notes, Due 12/1/2027 (euro-denominated) 	2.75 % 	1,138 	1,175
0.790% 3-Year Senior Notes, Due 1/6/2028 (Swiss franc-denominated) 	1.34 % 	109 	111
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 	0.77 % 	911 	940
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 	1.79 % 	408 	416
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 	0.90 % 	179 	185
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 	1.46 % 	683 	705
1.75% 7-Year Senior Notes, Due 10/15/2028 	1.89 % 	700 	700
5.00% 5-Year Senior Notes, Due 1/31/2029 	5.24 % 	1,000 	1,000
1.125% 4-Year Senior Notes, Due 3/7/2029 (Swiss franc-denominated) 	1.26 % 	389 	397
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 	2.08 % 	797 	822
2.60% 10-Year Senior Notes, Due 10/1/2029 	2.74 % 	900 	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 	1.44 % 	29 	30
1.120% 5-Year Senior Notes, Due 1/6/2030 (Swiss franc-denominated) 	1.25 % 	289 	295
4.977% 7-Year Senior Notes, Due 8/10/2030 	5.12 % 	750 	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 	0.89 % 	1,992 	2,056
4.215% 5-Year Senior Notes, Due 2/12/2031 	4.41 % 	1,000 	—
4.200% 5.5-Year Senior Notes Due 3/1/2031 	4.41 % 	500 	500
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 	1.13 % 	1,025 	1,057
2.00% 10-Year Senior Notes, Due 10/15/2031 	2.23 % 	1,200 	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 	1.92 % 	513 	524
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 	2.55 % 	683 	705
4.473% 7-Year Senior Notes, Due 10/7/2032 	4.62 % 	750 	750
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 	1.60 % 	39 	40
4.95% 10-Year Senior Notes, Due 11/21/2032 	5.09 % 	600 	600
1.4175% 8-Year Senior Notes, Due 3/7/2033 (Swiss franc-denominated) 	1.49 % 	432 	442
4.550% 7.3-Year Senior Notes, Due 6/15/2033 	4.73 % 	750 	—
5.086% 10-Year Senior Notes, Due 8/10/2033 	5.20 % 	1,000 	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 	1.21 % 	1,708 	1,762
5.20% 10-Year Senior Notes, Due 1/31/2034 	5.34 % 	500 	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 	3.76 % 	854 	881
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 	1.58 % 	133 	137
11

-- 11 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Effective interest rate at
June 27, 	June 27, 	December 31,
(Dollars in millions) 	2026 	2026 	2025
4.794% 10-Year Senior Notes, Due 10/7/2035 	4.91 % 	750 	750
3.628% 10-Year Senior Notes, Due 12/1/2035 (euro-denominated) 	3.70 % 	1,252 	1,292
4.902% 10-Year Senior Notes, Due 2/12/2036 	5.02 % 	1,300 	—
1.76% 10-Year Senior Notes, Due 3/3/2036 (Swiss franc-denominated) 	1.81 % 	358 	—
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 	2.10 % 	401 	410
1.520% 12-Year Senior Notes, Due 1/6/2037 (Swiss franc-denominated) 	1.56 % 	384 	392
1.6524% 12-Year Senior Notes, Due 3/6/2037 (Swiss franc-denominated) 	1.71 % 	266 	271
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 	2.94 % 	797 	822
4.894% 12-Year Senior Notes, Due 10/7/2037 	5.00 % 	500 	500
1.90% 12-Year Senior Notes, Due 3/3/2038 (Swiss franc-denominated) 	1.95 % 	310 	—
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 	1.73 % 	1,025 	1,057
2.01% 15-Year Senior Notes, Due 3/3/2041 (Swiss franc-denominated) 	2.05 % 	352 	—
2.80% 20-Year Senior Notes, Due 10/15/2041 	2.90 % 	1,200 	1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 	1.78 % 	1,423 	1,468
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 	2.13 % 	90 	93
5.404% 20-Year Senior Notes, Due 8/10/2043 	5.50 % 	600 	600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 	2.06 % 	179 	185
5.30% 30-Year Senior Notes, Due 2/1/2044 	5.37 % 	400 	400
1.49% 20-Year Senior Notes, Due 1/6/2045 (Swiss franc-denominated) 	1.54 % 	228 	233
1.8975% 20-Year Senior Notes, Due 3/7/2045 (Swiss franc-denominated) 	1.95 % 	167 	170
5.546% 20-Year Senior Notes, Due 2/12/2046 	5.64 % 	750 	—
2.11% 20-Year Senior Notes, Due 3/3/2046 (Swiss franc-denominated) 	2.18 % 	167 	—
4.10% 30-Year Senior Notes, Due 8/15/2047 	4.23 % 	750 	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 	1.98 % 	1,138 	1,175
1.47% 25-Year Senior Notes, Due 1/6/2050 (Swiss franc-denominated) 	1.49 % 	404 	413
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 	2.07 % 	854 	881
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 	2.43 % 	206 	212
2.06% 30-Year Senior Notes, Due 3/3/2056 (Swiss franc-denominated) 	2.09 % 	245 	—
Other 	— 	1
Total borrowings at par value 	42,592 	39,459
Unamortized discount 	(88) 	(94)
Unamortized debt issuance costs 	(220) 	(194)
Total borrowings at carrying value 	42,284 	39,172
Finance lease liabilities 	264 	213
Less: Short-term obligations and current maturities 	3,368 	3,533
Long-term obligations 	$ 	39,181 	$ 	35,852
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt
issuance costs.
See Note 4 for fair value information pertaining to the company’s long-term borrowings.
12

-- 12 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The
Facility expires on January 7, 2028. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), EURIBOR-based
rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative
and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio
(Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any
lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility,
it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of June 27, 2026, no borrowings were
outstanding under the Facility.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program,
a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial
paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may
be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes
are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed
or floating basis.
Senior Notes
Interest is payable annually on the euro and public Swiss franc-denominated fixed rate senior notes, quarterly on the euro-denominated floating rate senior note, and
semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes, and Japanese yen-denominated and Swiss franc-
denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued
interest, together with swap breakage costs payable to holders of the Japanese yen-denominated and Swiss franc-denominated private placement notes who have
entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase
agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under
borrowing arrangements. The company was in compliance with all covenants related to its senior notes at June 27, 2026.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes
outstanding as of June 27, 2026, included in the table above (collectively, the Euronotes) in registered public offerings: the Floating Rate Senior Notes due 2027,
the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 3.628% Senior Notes due 2035, the 1.625% Senior Notes due 2041, and the 2.00%
Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of
Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a
“finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and
repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and
cash flows of Thermo Fisher International are consolidated in the financial statements of the company.
13

-- 13 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 4. Fair Value Measurements
Fair Value Measurements
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
June 27,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2026 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	655 	$ 	655 	$ 	— 	$ 	—
Investments 	135 	43 	— 	92
Insurance contracts 	308 	— 	308 	—
Derivative contracts 	268 	— 	268 	—
Contingent consideration 	68 	— 	— 	68
Total assets 	$ 	1,434 	$ 	697 	$ 	576 	$ 	160
Liabilities
Derivative contracts 	$ 	667 	$ 	— 	$ 	667 	$ 	—
Contingent consideration 	178 	— 	— 	178
Total liabilities 	$ 	845 	$ 	— 	$ 	667 	$ 	178
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2025 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	6,907 	$ 	6,907 	$ 	— 	$ 	—
Bank time deposits 	250 	250 	— 	—
Investments 	103 	27 	— 	76
Insurance contracts 	280 	— 	280 	—
Derivative contracts 	685 	— 	685 	—
Contingent consideration 	67 	— 	— 	67
Total assets 	$ 	8,292 	$ 	7,184 	$ 	966 	$ 	143
Liabilities
Derivative contracts 	$ 	506 	$ 	— 	$ 	506 	$ 	—
Contingent consideration 	16 	— 	— 	16
Total liabilities 	$ 	522 	$ 	— 	$ 	506 	$ 	16
In the three- and six-month periods ended June 27, 2026, the company recorded $24 million and $23 million, respectively, of net gains/(losses) on investments,
which are included in other income/(expense) in the accompanying statements of income. In the three- and six-month periods ended June 28, 2025, the company
recorded $(3) million and $(2) million of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of
income.
The following table provides a rollforward of investments classified as level 3:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Investments
Beginning balance 	$ 	85 	$ 	31 	$ 	76 	$ 	21
Purchases 	8 	28 	16 	38
Ending balance 	$ 	92 	$ 	59 	$ 	92 	$ 	59
14

-- 14 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of a qualifying transaction), of the contingent
consideration asset:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 27, 2026
Contingent consideration asset
Beginning balance 	$ 	67 	$ 	67
Changes in fair value included in earnings 	1 	2
Ending balance 	$ 	68 	$ 	68
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as
well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration liabilities.
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Contingent consideration liabilities
Beginning balance 	$ 	168 	$ 	13 	$ 	16 	$ 	13
Acquisitions (including assumed balances) 	2 	— 	156 	—
Payments 	(9) 	(6) 	(9) 	(6)
Changes in fair value included in earnings 	17 	(2) 	16 	(1)
Currency translation 	(1) 	— 	(1) 	—
Ending balance 	$ 	178 	$ 	5 	$ 	178 	$ 	5
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
June 27, 2026 	December 31, 2025
(In millions) 	Carrying value 	Fair value 	Carrying value 	Fair value
Senior notes 	$ 	42,284 	$ 	39,604 	$ 	39,171 	$ 	36,606
Other 	— 	— 	1 	1
$ 	42,284 	$ 	39,604 	$ 	39,172 	$ 	36,607
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the
company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally
developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 5. Commitments and Contingencies
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential
costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup,
the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s
responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and
other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period
presented. At June 27, 2026, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2025
financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are
adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as
changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct
of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
15

-- 15 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise
from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial
issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending
litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an
unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in these interim financial
statements and notes, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the
company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of operations, financial
position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other
personal injury matters. At June 27, 2026, there have been no material changes to the accruals for pending product liability, workers compensation, and other
personal injury matters disclosed in the company’s 2025 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the
company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial
studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate
amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do
not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency
and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial
condition and ratings of its insurers on an ongoing basis.
Note 6. Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Revenues
Consumables 	$ 	5,073 	$ 	4,606 	$ 	9,794 	$ 	8,960
Instruments 	1,750 	1,644 	3,305 	3,270
Services 	5,171 	4,605 	9,899 	8,990
Consolidated revenues 	$ 	11,994 	$ 	10,855 	$ 	22,999 	$ 	21,219
Revenues by geographic region based on customer location are as follows:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Revenues
North America 	$ 	6,149 	$ 	5,722 	$ 	11,854 	$ 	11,235
Europe 	3,311 	2,830 	6,268 	5,454
Asia-Pacific 	2,104 	1,920 	4,075 	3,811
Other regions 	430 	383 	802 	720
Consolidated revenues 	$ 	11,994 	$ 	10,855 	$ 	22,999 	$ 	21,219
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
16

-- 16 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenues by business are as follows:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Revenues
Biosciences 	$ 	1,060 	$ 	1,075 	$ 	2,040 	$ 	2,068
Genetic sciences 	703 	679 	1,358 	1,356
BioProduction 	941 	745 	1,834 	1,416
Other 	112 	— 	219 	—
Life Sciences Solutions 	2,815 	2,499 	5,450 	4,840
Chromatography and mass spectrometry 	821 	784 	1,620 	1,557
Chemical analysis 	318 	292 	603 	578
Electron microscopy 	707 	652 	1,340 	1,311
Analytical Instruments 	1,847 	1,728 	3,563 	3,446
Clinical diagnostics 	290 	276 	561 	539
ImmunoDiagnostics 	248 	234 	478 	451
Microbiology 	166 	159 	326 	311
Transplant diagnostics 	134 	124 	255 	237
Healthcare market channel 	442 	407 	873 	880
Elimination of intrasegment revenues 	(75) 	(65) 	(145) 	(137)
Specialty Diagnostics 	1,205 	1,134 	2,346 	2,282
Laboratory products 	608 	601 	1,176 	1,183
Research and safety market channel 	2,036 	1,883 	3,863 	3,610
Pharma services 	1,893 	1,794 	3,634 	3,401
Clinical research 	2,396 	1,955 	4,524 	3,894
Elimination of intrasegment revenues and other 	(240) 	(238) 	(468) 	(453)
Laboratory Products and Biopharma Services 	6,693 	5,995 	12,729 	11,635
Elimination of intersegment revenues 	(565) 	(501) 	(1,089) 	(983)
Consolidated revenues 	$ 	11,994 	$ 	10,855 	$ 	22,999 	$ 	21,219
Restructuring and Other Costs
In the first six months of 2026, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort
to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2026, severance
actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
As of July 31, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will
result in additional charges of approximately $220 million, primarily in 2026, and expects to identify additional actions in future periods.
Restructuring and other costs are as follows:
Three months ended 	Six months ended
(In millions) 	June 27, 2026 	June 27, 2026
Life Sciences Solutions 	$ 	13 	$ 	23
Analytical Instruments 	17 	21
Specialty Diagnostics 	3 	3
Laboratory Products and Biopharma Services 	62 	95
Corporate 	4 	7
$ 	98 	$ 	147
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying
balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income are summarized in the notes to the table.
17

-- 17 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In millions) 	Total (a)
Balance at December 31, 2025 	$ 	70
Net restructuring charges incurred in 2026 (b) 	72
Payments 	(65)
Currency translation and other 	(5)
Balance at June 27, 2026 	$ 	72
(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b) Excludes $76 million of net charges, principally $60 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services segment.
The company expects to pay accrued restructuring costs primarily through 2026.
Earnings per Share
The company’s earnings per share are as follows:
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(In millions except per share amounts) 	2026 	2025 	2026 	2025
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,736 $ 	1,617 $ 	3,387 $ 	3,124
Basic weighted average shares 	371 	378 	372 	378
Plus effect of: stock options and restricted stock units 	— 	— 	— 	1
Diluted weighted average shares 	371 	378 	372 	378
Basic earnings per share 	$ 	4.68 $ 	4.28 $ 	9.11 $ 	8.27
Diluted earnings per share 	$ 	4.68 $ 	4.28 $ 	9.10 $ 	8.26
Antidilutive stock options excluded from diluted weighted average shares 	4 	4 	3 	3
Note 7. Income Taxes
The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to
income before provision for income taxes due to the following:
Six months ended
(Dollars in millions) 	June 27, 2026 	June 28, 2025
U.S. federal statutory tax rate 	$ 	768 	21.0 % $ 	699 	21.0 %
State and local income taxes, net of federal income tax effect 	44 	1.2 % 	43 	1.3 %
Foreign tax effects 	(431) 	(11.8)% 	(73) 	(2.2)%
Effect of changes in tax laws or rates enacted in the current period 	— 	0.0 % 	5 	0.1 %
Effect of cross-border tax laws 	129 	3.5 % 	46 	1.4 %
Tax credits 	(96) 	(2.6)% 	(99) 	(3.0)%
Changes in valuation allowances 	— 	0.0 % 	(122) 	(3.7)%
Nontaxable or nondeductible items 	7 	0.2 % 	(5) 	(0.1)%
Changes in unrecognized tax benefits 	28 	0.8 % 	(28) 	(0.8)%
Other adjustments 	(212) 	(5.8)% 	(279) 	(8.4)%
Effective tax rate 	$ 	238 	6.5 % $ 	187 	5.6 %
During the first quarter of 2026, the company recorded a deferred tax benefit of $175 million resulting from the recognition of tax attributes related to
domestication transactions. During the second quarter of 2026, the company recorded a deferred tax benefit of $148 million in jurisdictions where the deferred tax
assets are now expected to be realized due to forecasted income.
During the first quarter of 2025, the company recorded a deferred tax benefit of $125 million resulting from the recognition of a tax attribute related to a
domestication transaction. During the second quarter of 2025, the company recorded a deferred tax benefit of $153 million related to capital losses generated as part
of intra-entity transactions and a $93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income.
18

-- 18 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S.
federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S.
federal statutory rate.
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted. The OBBBA includes a broad range of provisions, such as the permanent extension of
certain otherwise expiring provisions, modifications to the international tax framework and the reinstatement of favorable tax treatment for certain business
provisions. The OBBBA made changes to certain US corporate tax provisions which are effective beginning in 2026. The enactment of the OBBBA is not material.
Unrecognized Tax Benefits
As of June 27, 2026, the company had $0.41 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 	2026
Balance at beginning of year 	$ 	419
Additions due to acquisitions 	5
Additions for tax positions of current year 	3
Additions for tax positions of prior years 	21
Reductions for tax positions of prior years 	(1)
Settlements 	(43)
Balance at end of period 	$ 	405
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income/(Loss)
Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:
(In millions)
Cumulative
translation
adjustment
Unrealized
gains/(losses) on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment 	Total
Three months ended June 27, 2026
Balance at March 28, 2026 	$ 	(2,234) 	$ 	(22) 	$ 	(242) 	$ 	(2,497)
Other comprehensive income/(loss) before reclassifications 	39 	— 	— 	39
Amounts reclassified from accumulated other comprehensive income/(loss) 	(4) 	1 	1 	(2)
Net other comprehensive income/(loss) 	35 	1 	1 	37
Balance at June 27, 2026 	$ 	(2,199) 	$ 	(21) 	$ 	(241) 	$ 	(2,460)
Six months ended June 27, 2026
Balance at December 31, 2025 	$ 	(2,181) 	$ 	(23) 	$ 	(245) 	$ 	(2,448)
Other comprehensive income/(loss) before reclassifications 	(19) 	— 	2 	(17)
Amounts reclassified from accumulated other comprehensive income/(loss) 	2 	1 	2 	5
Net other comprehensive income/(loss) 	(17) 	1 	4 	(12)
Balance at June 27, 2026 	$ 	(2,199) 	$ 	(21) 	$ 	(241) 	$ 	(2,460)
19

-- 19 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 9. Supplemental Cash Flow Information
Supplemental cash flow information is as follows:
Six months ended
(In millions) 	June 27, 2026 	June 28, 2025
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 	$ 	221 	$ 	206
Fair value of acquisition contingent consideration 	115 	—
Finance lease ROU assets obtained in exchange for new finance lease liabilities 	54 	—
Declared but unpaid dividends 	177 	165
Issuance of stock upon vesting of restricted stock units 	69 	69
Excise tax from stock repurchases 	38 	17
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
(In millions) 	June 27, 2026 	December 31, 2025
Cash and cash equivalents 	$ 	4,064 	$ 	9,852
Restricted cash included in other current assets 	11 	5
Restricted cash included in other assets 	22 	22
Cash, cash equivalents and restricted cash 	$ 	4,096 	$ 	9,879
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming cash in China awaiting
government administrative clearance.
Note 10. Derivatives
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
(In millions) 	June 27, 2026 	December 31, 2025
Notional amount
Cross-currency interest rate swaps designated as net investment hedge - euro 	$ 	— 	$ 	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 	1,100 	4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 	11,800 	5,000
Currency exchange contracts 	1,496 	2,248
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance
sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
Fair value – assets 	Fair value – liabilities
June 27, 	December 31, 	June 27, 	December 31,
(In millions) 	2026 	2025 	2026 	2025
Derivatives designated as hedging instruments
Cross-currency interest rate swaps 	$ 	267 	$ 	684 	$ 	666 	$ 	504
Derivatives not designated as hedging instruments
Currency exchange contracts 	1 	2 	1 	2
Total derivatives 	$ 	268 	$ 	685 	$ 	667 	$ 	506
20

-- 20 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides information on the company’s derivative positions subject to master netting arrangements, presented on a net basis, had the company
elected to offset the asset and liability balances of its positions in the consolidated balance sheets:
Fair value – assets 	Fair value – liabilities
June 27, 	December 31, 	June 27, 	December 31,
(In millions) 	2026 	2025 	2026 	2025
Gross amounts recognized in the consolidated balance sheets 	$ 	268 	$ 	685 	$ 	667 	$ 	506
Gross amounts subject to offset in master netting arrangements not offset in
the consolidated balance sheets 	(189) 	(319) 	(189) 	(319)
Total derivatives, net 	$ 	79 	$ 	366 	$ 	478 	$ 	187
The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other current assets, other assets, other
current liabilities, or other long-term liabilities. The fair value of the currency exchange contracts is included in the accompanying balance sheets under the captions
other current assets or other accrued expenses.
Gain/(loss) recognized
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(In millions) 	2026 	2025 	2026 	2025
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive income/(loss)
to interest expense 	$ 	(1) 	$ 	(1) 	$ 	(2) 	$ 	(2)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in cumulative translation adjustment within other comprehensive
income/(loss) 	119 	(788) 	341 	(1,238)
Cross-currency interest rate swaps
Included in cumulative translation adjustment within other comprehensive
income/(loss) 	(43) 	(515) 	(98) 	(634)
Included in interest expense 	99 	67 	196 	134
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 	— 	(3) 	1 	(2)
Included in other income/(expense) 	(7) 	3 	(1) 	13
Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting
losses and gains on the underlying hedged transactions.
See Note 1 to the consolidated financial statements for 2025 included in the company’s Annual Report on Form 10-K for additional information on the company’s
risk management objectives and strategies.
Note 11. Business Segment Information
Business Segment Information
The company’s financial performance is reported in four segments. During 2026, there have been no changes to the company’s basis of segmentation or in the basis
of measurement of segment income. Other segment items included in the below tables consist of stock-based compensation and other incentive compensation
expenses, allocations of corporate expenses and certain overhead expenses, as well as elimination of intersegment and intrasegment profits. Prior period segment
expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.
21

-- 21 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2026
Three months ended June 27, 2026
(In millions) Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,355 $ 	1,799 $ 	1,188 $ 	6,652 $ 	11,994
Intersegment revenues 	460 	47 	17 	41 	565
2,815 	1,847 	1,205 	6,693 	12,559
Elimination of intersegment revenues 	(565)
Consolidated revenues 	$ 	11,994
Segment Income
Cost of revenues 	1,080 	925 	699 	5,150
Selling, general, and administrative expenses 	500 	315 	177 	677
Research and development expenses 	140 	140 	45 	27
Other segment items 	54 	43 	(50) 	(97)
Segment income 	1,041 	424 	334 	936 	2,735
Unallocated amounts
Cost of revenues adjustments 	(28)
Selling, general and administrative expenses adjustments 	(36)
Restructuring and other costs 	(98)
Amortization of acquisition-related intangible assets 	(485)
Interest income 	207
Interest expense 	(401)
Other income/(expense) 	31
Consolidated income before income taxes 	$ 	1,924
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	98,003 $ 	3,508 $ 	3,187 $ 	1,323 $ 	7,152 $ 	113,174
Purchases of property, plant and equipment 	90 	59 	17 	24 	260 	450
Depreciation of property, plant and equipment 	— 	69 	27 	20 	216 	331
22

-- 22 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
Three months ended June 28, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,115 $ 	1,669 $ 	1,118 $ 	5,953 $ 	10,855
Intersegment revenues 	385 	58 	16 	42 	501
2,499 	1,728 	1,134 	5,995 	11,356
Elimination of intersegment revenues 	(501)
Consolidated revenues 	$ 	10,855
Segment Income
Cost of revenues 	925 	902 	640 	4,667
Selling, general, and administrative expenses 	467 	317 	183 	595
Research and development expenses 	135 	145 	47 	14
Other segment items 	54 	39 	(42) 	(106)
Segment income 	919 	325 	306 	825 	2,375
Unallocated amounts
Cost of revenues adjustments 	(10)
Selling, general and administrative expenses adjustments 	(20)
Restructuring and other costs 	(82)
Amortization of acquisition-related intangible assets 	(429)
Interest income 	297
Interest expense 	(404)
Other income/(expense) 	(19)
Consolidated income before income taxes 	$ 	1,709
(In millions) Unallocated
amounts Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	87,013 $ 	3,142 $ 	3,070 $ 	1,295 $ 	6,711 $ 	101,230
Purchases of property, plant and equipment 	25 	25 	13 	25 	206 	294
Depreciation of property, plant and equipment 	— 	56 	26 	23 	152 	256
23

-- 23 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2026
Six months ended June 27, 2026
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	4,574 $ 	3,466 $ 	2,312 $ 	12,647 $ 	22,999
Intersegment revenues 	877 	96 	34 	82 	1,089
5,450 	3,563 	2,346 	12,729 	24,088
Elimination of intersegment revenues 	(1,089)
Consolidated revenues 	$ 	22,999
Segment Income
Cost of revenues 	2,084 	1,801 	1,356 	9,907
Selling, general, and administrative expenses 	996 	628 	354 	1,274
Research and development expenses 	271 	278 	89 	41
Other segment items 	105 	76 	(99) 	(208)
Segment income 	1,994 	779 	646 	1,714 	5,133
Unallocated amounts
Cost of revenues adjustments 	(42)
Selling, general and administrative expenses adjustments 	(79)
Restructuring and other costs 	(147)
Amortization of acquisition-related intangible assets 	(915)
Interest income 	440
Interest expense 	(755)
Other income/(expense) 	22
Consolidated income before income taxes 	$ 	3,658
(In millions) Unallocated
amounts Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	98,003 $ 	3,508 $ 	3,187 $ 	1,323 $ 	7,152 $ 	113,174
Purchases of property, plant and equipment 	117 	79 	52 	59 	518 	826
Depreciation of property, plant and equipment 	— 	139 	53 	44 	402 	638
24

-- 24 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
Six months ended June 28, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	4,069 $ 	3,346 $ 	2,248 $ 	11,556 $ 	21,219
Intersegment revenues 	771 	99 	34 	79 	983
4,840 	3,446 	2,282 	11,635 	22,202
Elimination of intersegment revenues 	(983)
Consolidated revenues 	$ 	21,219
Segment Income
Cost of revenues 	1,781 	1,737 	1,319 	9,077
Selling, general, and administrative expenses 	935 	631 	354 	1,183
Research and development expenses 	274 	282 	92 	27
Other segment items 	98 	71 	(93) 	(209)
Segment income 	1,753 	724 	610 	1,557 	4,644
Unallocated amounts
Cost of revenues adjustments 	(21)
Selling, general and administrative expenses adjustments 	(34)
Restructuring and other costs 	(180)
Amortization of acquisition-related intangible assets 	(859)
Interest income 	501
Interest expense 	(707)
Other income/(expense) 	(16)
Consolidated income before income taxes 	$ 	3,329
(In millions) Unallocated
amounts Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	87,013 $ 	3,142 $ 	3,070 $ 	1,295 $ 	6,711 $ 	101,230
Purchases of property, plant and equipment 	61 	69 	57 	58 	412 	656
Depreciation of property, plant and equipment 	— 	114 	50 	44 	324 	532
25

-- 25 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 12. Acquisitions and Divestiture
Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill,
primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.
These synergies include: the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of
the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company
products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying
financial statements from their respective dates of acquisition.
2026
On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider
of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly complementary clinical research offerings,
enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity. The goodwill
recorded as a result of this business combination is not tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions) 	Clario
Purchase price
Cash paid 	$ 	5,806
Debt settled 	3,180
Purchase price payable 	121
Fair value of contingent consideration 	108
Cash acquired 	(117)
$ 	9,098
Net assets acquired
Definite-lived intangible assets
Customer relationships 	$ 	2,510
Product technology 	844
Trade names 	19
Backlog 	423
Goodwill 	5,934
Net other assets/(liabilities) 	386
Contract liabilities 	(375)
Deferred tax assets/(liabilities) 	(645)
$ 	9,098
The preliminary allocation of the purchase price for the acquisition of Clario is based on the estimates of the fair value of the purchase price and net assets acquired
and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, contract liabilities and the related deferred taxes. Measurements of
these items inherently require significant estimates and assumptions.
In 2026, the company also acquired, within the Analytical Instruments segment, two proteomics software companies including one in the U.S. and one in Germany,
further strengthening our mass spectrometry and proteomics software capabilities.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2026 are 20 years for customer relationships, 7 years for product
technology, 3 years for trade names, and 6 years for backlog. The weighted-average amortization period for all definite-lived intangible assets acquired in 2026 is
15 years.
26

-- 26 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification
and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The
business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and
downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and
medical device manufacturing. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)
Filtration and
separation business
Purchase price
Cash paid 	$ 	3,939
Fair value of contingent consideration 	(66)
Cash acquired 	(9)
$ 	3,865
Net assets acquired
Property, plant and equipment 	$ 	469
Definite-lived intangible assets
Customer relationships 	1,116
Product technology 	388
Trade names 	51
Goodwill 	2,065
Net other assets/(liabilities) 	152
Deferred tax assets/(liabilities) 	(376)
$ 	3,865
The preliminary allocation of the purchase price for the acquisition of Solventum’s Filtration and Separation business is based on the estimates of the fair value of
the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to inventories and deferred taxes. Measurements of
these items inherently require significant estimates and assumptions.
In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet
the growing demand from pharma and biotech customers for U.S. manufacturing capacity.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years for product
technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired in 2025 is 18 years.
Divestiture
On April 27, 2026, the company entered into an agreement to sell its microbiology business to Astorg for approximately $1.075 billion, consisting of cash and a $50
million seller note. The business is part of the Specialty Diagnostics segment. The sale is subject to customary closing conditions and applicable regulatory
approvals and is expected to close in the third quarter of 2026. The assets and liabilities of the microbiology business were as follows as of June 27, 2026:
(In millions)
Current assets 	$ 	228
Long-term assets 	760
Current liabilities 	71
Long-term liabilities 	45
27

-- 27 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains “forward-looking statements”, within the meaning of the
Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are based on current expectations and
assumptions that are subject to risks and uncertainties, and are often identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “may,” “will,” “should,” or similar expressions or words with similar meanings. Any statements contained herein that are not statements of historical
fact should be considered forward-looking statements.
Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations include, among others, statements
regarding:
• financial expectations, including projections of revenues, expenses, margins, earnings, cash flows, liquidity, capital allocation plans, and tax matters;
• operational matters, including business strategies, productivity initiatives, restructuring activities, cost-reduction programs, and new product or service
developments;
• market and competitive conditions, including customer demand trends, industry dynamics, pricing, and competitive positioning;
• strategic actions, including planned acquisitions, divestitures, investments, and partnerships;
• legal, regulatory, macroeconomic, geopolitical, public health, supply chain, technology, and cybersecurity developments and their potential impacts
on the company; and
• the timing and outcomes of any of the foregoing.
Each forward-looking statement contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations is inherently uncertain
and involves significant risks, assumptions, and factors that could cause actual results to differ materially from those expressed or implied. Important risks and
uncertainties that could cause such differences are detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended
December 31, 2025, which is on file with the Securities and Exchange Commission (SEC).
Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations speak only as of the dates on which
they are made. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, in the event of
new information, future developments, or otherwise, except as required by law.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-
GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this
“Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying unrounded amounts. As a
result, the sum of components may not equal corresponding totals due to rounding.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex
analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing
therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The
company’s operations fall into four segments (Note 11): Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and
Biopharma Services.
28

-- 28 of 43 --

THERMO FISHER SCIENTIFIC INC.
Consolidated Results
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(Dollars in millions except per share amounts) 	2026 	2025 	Change 	2026 	2025 	Change
Revenues 	$ 	11,994 	$ 	10,855 	10 % $ 	22,999 	$ 	21,219 	8 %
GAAP operating income 	2,087 	1,834 	14 % 	3,950 	3,551 	11 %
GAAP operating income margin 	17.4 % 	16.9 % 	0.5 pt 	17.2 % 	16.7 % 	0.5 pt
Adjusted operating income (non-GAAP measure) 	2,735 	2,375 	15 % 	5,133 	4,644 	11 %
Adjusted operating income margin (non-GAAP measure) 	22.8 % 	21.9 % 	0.9 pt 	22.3 % 	21.9 % 	0.4 pt
GAAP diluted earnings per share attributable to Thermo
Fisher Scientific Inc. 	4.68 	4.28 	9 % 	9.10 	8.26 	10 %
Adjusted earnings per share (non-GAAP measure) 	6.03 	5.36 	13 % 	11.47 	10.51 	9 %
Organic Revenue Growth
Three months ended 	Six months ended
June 27, 2026 	June 27, 2026
Revenue growth 	10 % 	8 %
Impact of acquisitions 	5 % 	4 %
Impact of currency translation 	1 % 	2 %
Organic revenue growth (non-GAAP measure) 	5 % 	3 %
During the second quarter of 2026, customer activity continued to strengthen across our end markets. Revenue growth was strong in the pharma and biotech market,
with performance driven by strengthening underlying market conditions. Revenues in the academic and government market grew, and growth in the industrial and
applied market was strong, both driven by customer demand for our innovative high-end instruments. Revenue to customers in the diagnostics and healthcare
market was also strong. During the second quarter of 2026, sales increased across all major geographies. Revenue growth was strong in Europe and Asia-Pacific,
including China. Contributions to organic revenue during the second quarter of 2026 were led by the Laboratory Products and Biopharma Services segment and the
Analytical Instruments segment.
During the first six months of 2026, revenue growth in the pharma and biotech market was strong, with performance driven by strengthening underlying market
conditions. Revenues to customers in the industrial and applied market increased, driven by customer demand for our innovative high-end instruments. Revenues in
the academic and government as well as the diagnostics and healthcare market were flat. During the first six months of 2026, sales grew in North America and Asia-
Pacific, including China. Revenue growth in Europe was strong. Contributions to organic revenue during the first six months of 2026 were led by the Laboratory
Products and Biopharma Services segment.
The company continues to execute its proven growth strategy which consists of three pillars:
• High-impact innovation;
• Our trusted partner status with customers; and
• Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin increased in the second quarter of 2026 due primarily to strong productivity improvements,
offset in part by unfavorable business mix.
GAAP operating income margin and adjusted operating income margin increased in the first six months of 2026 due primarily to very strong productivity
improvements, offset in part by unfavorable business mix and strategic investments.
The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic
sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other
expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this
discussion to productivity improvements generally refer to the impact of its Practical Process Improvement (PPI) Business System to address inflation, drive cost
efficiencies and improve profitability. The benefits of PPI include optimized price realization, reduced costs resulting from implementing continuous improvement
methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and
low cost region manufacturing.
29

-- 29 of 43 --

THERMO FISHER SCIENTIFIC INC.
Notable Recent Acquisitions
On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider
of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly complementary clinical research offerings,
enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity.
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification
and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The
business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and
downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and
medical device manufacturing.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 11 to the
Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2025. Accordingly, the following segment data are reported on this basis.
Three months ended 	Six months ended
(Dollars in millions) 	June 27, 2026 	June 28, 2025 	June 27, 2026 	June 28, 2025
Revenues
Life Sciences Solutions 	$ 	2,815 $ 	2,499 $ 	5,450 $ 	4,840
Analytical Instruments 	1,847 	1,728 	3,563 	3,446
Specialty Diagnostics 	1,205 	1,134 	2,346 	2,282
Laboratory Products and Biopharma Services 	6,693 	5,995 	12,729 	11,635
Eliminations 	(565) 	(501) 	(1,089) 	(983)
Consolidated revenues 	$ 	11,994 $ 	10,855 $ 	22,999 $ 	21,219
Life Sciences Solutions
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	2,815 	$ 	2,499 	13 % 	9 % 	1 % 	3 %
Segment income 	1,041 	919 	13 %
Segment income margin 	37.0 % 	36.8 % 	0.2 pt
The increase in organic revenues in the second quarter of 2026 was primarily driven by the bioproduction business. On a reported basis, the bioproduction business
grew $196 million, which contributed 8 percentage points of reported growth in the segment, driven by higher demand from pharma and biotech customers, as well
as the impact from the 2025 acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from very strong
productivity improvements, offset in part by the impact from the acquisition of the filtration and separation business and unfavorable business mix.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	5,450 	$ 	4,840 	13 % 	9 % 	2 % 	2 %
Segment income 	1,994 	1,753 	14 %
Segment income margin 	36.6 % 	36.2 % 	0.4 pt
The increase in organic revenues in the first six months of 2026 was driven by the bioproduction business, partially offset by declines in the biosciences business.
On a reported basis, the bioproduction business grew $417 million, driven by higher demand from pharma and biotech customers, as well as the impact from the
2025 acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from exceptionally strong productivity
improvements, partially offset by the impact from the filtration and separation business acquisition and unfavorable business mix.
30

-- 30 of 43 --

THERMO FISHER SCIENTIFIC INC.
Analytical Instruments
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	1,847 	$ 	1,728 	7 % 	0 % 	0 % 	7 %
Segment income 	424 	325 	30 %
Segment income margin 	23.0 % 	18.8 % 	4.2 pt
The increase in organic revenues in the second quarter of 2026 was driven by growth across all three of the segment’s businesses, led by the electron microscopy
business. On a reported basis, the electron microscopy, chromatography and mass spectrometry, and chemical analysis businesses increased $55 million, $37
million, and $26 million, respectively. The increase in segment income margin was driven by very strong productivity improvements, favorable volume leverage,
and the favorable impact of foreign exchange.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	3,563 	$ 	3,446 	3 % 	0 % 	1 % 	2 %
Segment income 	779 	724 	8 %
Segment income margin 	21.9 % 	21.0 % 	0.9 pt
The increase in organic revenues in the first six months of 2026 was primarily due to growth in the chromatography and mass spectrometry business. On a reported
basis, the chromatography and mass spectrometry business grew $63 million, which contributed 2 percentage points of reported growth in the segment. The
increase in segment income margin was primarily driven by productivity improvements.
Specialty Diagnostics
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	1,205 	$ 	1,134 	6 % 	0 % 	1 % 	5 %
Segment income 	334 	306 	9 %
Segment income margin 	27.7 % 	27.0 % 	0.7 pt
The increase in organic revenues in the second quarter of 2026 was primarily driven by growth in the healthcare market channel and immunodiagnostics business.
On a reported basis, the healthcare market channel, clinical diagnostics business, and immunodiagnostics business increased $36 million, $14 million, and $14
million, respectively. The increase in segment income margin was driven by favorable volume leverage and strong productivity, offset in part by unfavorable
business mix.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	2,346 	$ 	2,282 	3 % 	0 % 	2 % 	1 %
Segment income 	646 	610 	6 %
Segment income margin 	27.6 % 	26.7 % 	0.9 pt
The increase in organic revenues in the first six months of 2026 was principally driven by growth in the transplant diagnostics business and the immunodiagnostics
business. On a reported basis, the immunodiagnostics business grew $26 million, and the clinical diagnostics business grew $22 million, which were the principal
drivers of reported revenue growth in the segment. The increase in segment income margin was primarily due to strong productivity improvements.
31

-- 31 of 43 --

THERMO FISHER SCIENTIFIC INC.
Laboratory Products and Biopharma Services
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	6,693 	$ 	5,995 	12 % 	6 % 	1 % 	5 %
Segment income 	936 	825 	13 %
Segment income margin 	14.0 % 	13.8 % 	0.2 pt
The increase in organic revenues in the second quarter of 2026 was primarily due to growth in the research and safety market channel and the clinical research
business. On a reported basis, the clinical research business grew $441 million, which contributed 7 percentage points of reported growth in the segment, primarily
driven by the impact of the Clario acquisition. The research and safety market channel and pharma services business grew $153 million and $99 million,
respectively, which contributed 3 percentage points and 2 percentage points, respectively, of reported growth in the segment. The increase in segment income
margin was driven by strong productivity improvements and the impact of acquisitions, partially offset by unfavorable business mix and strategic investments.
Six months ended
Organic (non-
GAAP measure)	(Dollars in millions)
June 27,
2026
June 28,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	12,729 	$ 	11,635 	9 % 	4 % 	1 % 	5 %
Segment income 	1,714 	1,557 	10 %
Segment income margin 	13.5 % 	13.4 % 	0.1 pt
The increase in organic revenues in the first six months of 2026 was primarily due to growth in the clinical research business and research and safety market
channel. On a reported basis, the clinical research business grew $630 million, which contributed 5 percentage points of reported growth in the segment, primarily
driven by the impact of the Clario acquisition. The research and safety market channel and pharma services business grew $252 million and $233 million,
respectively, which each contributed 2 percentage points of reported growth in the segment. The increase in segment income margin was primarily due to very
strong productivity improvements and the impact of acquisitions, largely offset by unfavorable business mix and strategic investments.
Non-operating Items
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(Dollars and shares in millions) 	2026 	2025 	2026 	2025
Net interest expense 	$ 	194 	$ 	107 	$ 	314 	$ 	206
GAAP other income/(expense) 	31 	(19) 	22 	(16)
Adjusted other income/(expense) (non-GAAP measure) 	— 	(14) 	(7) 	(12)
GAAP tax rate 	8.7 % 	5.4 % 	6.5 % 	5.6 %
Adjusted tax rate (non-GAAP measure) 	11.6 % 	10.0 % 	11.1 % 	10.0 %
Weighted average diluted shares 	371 	378 	372 	378
Net interest expense (interest expense less interest income) in the second quarter and first six months of 2026 increased, due primarily to the increase in debt for
general corporate purposes and the company’s capital deployment initiatives, which included financing stock buybacks, paying dividends, and acquiring Clario
(Note 12). In the second quarter and first six months of 2026, the company’s net interest expense was reduced by approximately $98 million and $194 million,
respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements. In the second quarter and first six months of 2025, the
company’s net interest expense was reduced by approximately $66 million and $133 million, respectively, as a result of its interest rate swap and cross-currency
interest rate swap arrangements (Note 10).
GAAP other income/(expense) and adjusted other income/(expense) include currency transaction gains/losses on non-operating monetary assets and liabilities, and
net periodic pension benefit cost/income, excluding the service cost component.
GAAP other income/(expense) in the first six months of 2026 and 2025 also includes $23 million and $2 million, respectively, of net gains/(losses) on investments.
GAAP other income/(expense) in the second quarter of 2026 also includes $6 million of business interruption recoveries. GAAP other income/(expense) in the
second quarter of 2025 also includes $5 million of charges for settlement of pension plans.
32

-- 32 of 43 --

THERMO FISHER SCIENTIFIC INC.
The company’s GAAP and adjusted tax rates in the first six months of 2026 were impacted by a $175 million deferred tax benefit resulting from the recognition of
tax attributes related to domestication transactions and a deferred tax benefit of $148 million in jurisdictions where the deferred tax assets are now expected to be
realized due to forecasted income. The company’s GAAP and adjusted tax rates in the first six months of 2025 were impacted by a $125 million deferred tax benefit
resulting from the recognition of a tax attribute related to a domestication transaction, a deferred tax benefit of $153 million related to capital losses generated as
part of intra-entity transactions and a $93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income
(Note 7).
The effective tax rates in both 2026 and 2025 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility
of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting
purposes and are expected to total approximately $1.5 billion in 2026.
The company expects its GAAP effective tax rate in 2026 will be between 9% and 11% based on currently forecasted rates of profitability in the countries in which
the company conducts business and generates foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income
tax factors and events. The company expects its adjusted tax rate will be approximately 11.5% in 2026.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The
company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the
statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a
change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income.
Weighted average diluted shares decreased in 2026 compared to 2025, primarily due to share repurchases, net of option dilution.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via
mergers and acquisitions and secondarily via share buybacks and dividends.
(In millions) 	June 27, 2026 	December 31, 2025
Cash and cash equivalents 	$ 	4,064 	$ 	9,852
Short-term investments 	— 	253
Total debt 	42,549 	39,384
Approximately half of the company’s cash balances and cash flows from operations are generated outside the U.S. The company uses its non-U.S. cash for needs
outside of the U.S., including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also
transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend
received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company
does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its
revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24
months.
As of June 27, 2026, the company’s short-term obligations and current maturities of long-term obligations totaled $3.37 billion. During the first quarter of 2026, the
company amended its revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit to extend the
expiration date by one year to January 7, 2028 (Note 3). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding
commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of June 27, 2026, no borrowings were outstanding
under the company’s revolving credit facility.
33

-- 33 of 43 --

THERMO FISHER SCIENTIFIC INC.
Six months ended
(In millions) 	June 27, 2026 	June 28, 2025
Net cash provided by operating activities 	$ 	3,317 	$ 	2,122
Net cash used in investing activities 	(8,797) 	(815)
Net cash used in financing activities 	(478) 	(1,093)
Free cash flow (non-GAAP measure) 	2,503 	1,479
Operating Activities
During the first six months of 2026, net income provided substantially all cash from operating activities. Cash payments for income taxes were $0.67 billion during
the first six months of 2026.
During the first six months of 2025, cash provided by net income was offset in part by investments in working capital. Changes in other assets and liabilities used
cash of $1.43 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $1.20 billion during the
first six months of 2025.
Investing Activities
During the first six months of 2026, acquisitions used cash of $8.87 billion. Purchases of property, plant and equipment for capacity and capability investments used
cash of $0.83 billion. The company’s investing activities also included $0.48 billion of net proceeds from terminations of cross-currency interest rate swaps.
During the first six months of 2025, the company’s investing activities included purchases of $0.66 billion for the purchase of property, plant and equipment for
capacity and capability investments.
The company expects that for all of 2026, expenditures for property, plant and equipment, net of disposals, will be between $1.9 billion and $2.1 billion.
Financing Activities
During the first six months of 2026, issuance of debt provided $5.24 billion of cash. Repayment of debt used cash of $1.41 billion. The company’s financing
activities also included the repurchase of $4.00 billion of the company’s common stock (6.9 million shares), and the payment of $0.34 billion in cash dividends. On
November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion of the company’s common stock. All of the shares of common stock
repurchased by the company during the first six months of 2026 were under this program. At July 31, 2026, $1.00 billion was available for future repurchases of the
company’s common stock under this authorization.
During the first six months of 2025, issuance of debt provided $2.84 billion of cash. Repayment of debt used cash of $1.63 billion. The company’s financing
activities also included the repurchase of $2.00 billion of the company’s common stock (3.6 million shares) and the payment of $0.31 billion in cash dividends.
The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, did not change materially
subsequent to December 31, 2025, except in connection with the completion of the Clario acquisition, which occurred on March 24, 2026 (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with GAAP, we use certain non-GAAP financial measures such as organic revenue growth, which is
reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue
growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to
consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast
and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the
use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and
future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to
previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-
making and for compensation purposes. To calculate these measures we exclude, as applicable:
• Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party
costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for
pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
34

-- 34 of 43 --

THERMO FISHER SCIENTIFIC INC.
• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating
facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not
indicative of our normal operating costs.
• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot
be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant
litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of
our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions
may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that
are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from
enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for
future periods.
We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use
in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is
not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from
the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a
substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly
comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(Dollars in millions except per share amounts) 	2026 	2025 	2026 	2025
Reconciliation of adjusted operating income
GAAP operating income 	$ 	2,087 	$ 	1,834 	$ 	3,950 	$ 	3,551
Cost of revenues adjustments (a) 	28 	10 	42 	21
Selling, general and administrative expenses adjustments (b) 	36 	20 	79 	34
Restructuring and other costs (c) 	98 	82 	147 	180
Amortization of acquisition-related intangible assets 	485 	429 	915 	859
Adjusted operating income (non-GAAP measure) 	$ 	2,735 	$ 	2,375 	$ 	5,133 	$ 	4,644
Reconciliation of adjusted operating income margin
GAAP operating income margin 	17.4 % 	16.9 % 	17.2 % 	16.7 %
Cost of revenues adjustments (a) 	0.2 % 	0.1 % 	0.2 % 	0.1 %
Selling, general and administrative expenses adjustments (b) 	0.3 % 	0.2 % 	0.3 % 	0.2 %
Restructuring and other costs (c) 	0.8 % 	0.8 % 	0.6 % 	0.9 %
Amortization of acquisition-related intangible assets 	4.0 % 	4.0 % 	4.0 % 	4.0 %
Adjusted operating income margin (non-GAAP measure) 	22.8 % 	21.9 % 	22.3 % 	21.9 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) 	$ 	31 	$ 	(19) 	$ 	22 	$ 	(16)
Adjustments (d) 	(31) 	5 	(29) 	4
Adjusted other income/(expense) (non-GAAP measure) 	$ 	— 	$ 	(14) 	$ 	(7) 	$ 	(12)
Reconciliation of adjusted tax rate
GAAP tax rate 	8.7 % 	5.4 % 	6.5 % 	5.6 %
Adjustments (e) 	2.9 % 	4.6 % 	4.6 % 	4.4 %
Adjusted tax rate (non-GAAP measure) 	11.6 % 	10.0 % 	11.1 % 	10.0 %
35

-- 35 of 43 --

THERMO FISHER SCIENTIFIC INC.
Three months ended 	Six months ended
June 27, 	June 28, 	June 27, 	June 28,
(Dollars in millions except per share amounts) 	2026 	2025 	2026 	2025
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc. 	$ 	4.68 $ 	4.28 $ 	9.10 $ 	8.26
Cost of revenues adjustments (a) 	0.07 	0.03 	0.11 	0.06
Selling, general and administrative expenses adjustments (b) 	0.10 	0.05 	0.21 	0.09
Restructuring and other costs (c) 	0.27 	0.22 	0.40 	0.48
Amortization of acquisition-related intangible assets 	1.31 	1.14 	2.46 	2.27
Other income/expense adjustments (d) 	(0.08) 	0.01 	(0.08) 	0.01
Income taxes adjustments (e) 	(0.34) 	(0.35) 	(0.79) 	(0.68)
Equity in earnings/losses of unconsolidated entities 	0.04 	(0.01) 	0.06 	0.03
Noncontrolling interests adjustments (f) 	— 	0.00 	— 	0.00
Adjusted EPS (non-GAAP measure) 	$ 	6.03 $ 	5.36 $ 	11.47 $ 	10.51
Reconciliation of free cash flow
GAAP net cash provided by operating activities 	$ 	2,125 $ 	1,399 $ 	3,317 $ 	2,122
Purchases of property, plant and equipment 	(450) 	(294) 	(826) 	(656)
Proceeds from sale of property, plant and equipment 	3 	1 	13 	13
Free cash flow (non-GAAP measure) 	$ 	1,678 $ 	1,105 $ 	2,503 $ 	1,479
(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale of inventory revalued
at the date of acquisition. Adjusted results in 2026 also exclude $9 million of transaction-related costs.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent acquisition consideration,
and accelerated depreciation on fixed assets to be abandoned due to facility consolidations.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and
other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.
(d) Adjusted results exclude net gains/losses on investments. Adjusted results in the first six months of 2026 also exclude $6 million of business interruption recoveries. Adjusted
results in the first six months of 2025 also exclude $5 million of charges for settlement of pension plans.
(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes,
and the tax impacts from audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2025 describe the
significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s
critical accounting policies during the first six months of 2026.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the
company’s Annual Report on Form 10-K for the year ended December 31, 2025.
36

-- 36 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the
company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure
controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal
quarter ended June 27, 2026, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 5 to our
Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”
Item 1A. Risk Factors
The risks that we believe are material to our investors are detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year
ended December 31, 2025 (which is on file with the SEC).
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
A summary of the share repurchase activity for the company’s second quarter of 2026 follows:
Period Total number of
shares purchased Average price
paid per share (1)
Total number of shares
purchased as part of
publicly announced plans or
programs (2)
Maximum dollar amount of
shares that may yet be
purchased under the plans or
programs (1)(2)
(in millions)
Fiscal April (Mar. 29 - Apr. 2) 	— 	$ 	— 	— 	$ 	2,000
Fiscal May (Apr. 3 - May 30) 	1,534,188 	478.98 	1,534,188 	1,265
Fiscal June (May 31 - Jun. 27) 	537,650 	493.16 	537,650 	1,000
Total second quarter 	2,071,838 	$ 	482.66 	2,071,838 	$ 	1,000
(1) Amounts exclude excise taxes and other transaction costs.
(2) On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion of the company’s common stock. All of the shares of common stock repurchased
by the company during 2026 were under this program.
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended June 27, 2026, no director or executive officer of the company adopted, modified or terminated a “Rule 10b5-1 trading
arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below:
Name and Title 	Action 	Plan Type 	Date of action
Scheduled
expiration of Rule
10b5-1 trading plan
Aggregate number of
securities to be
purchased or sold
Marc N. Casper, Chairman and Chief Executive Officer 	Modification¹ 	Rule 10b5-1 	4/27/2026 	6/9/2027 	108,888
Gianluca Pettiti, President and Chief Operating Officer 	Adoption 	Rule 10b5-1 	6/2/2026 	3/10/2027 	12,400
¹ Mr. Casper modified his Rule 10b5-1 trading arrangement, which was originally adopted on November 11, 2025. The aggregate number of shares reported in this table represents
the shares authorized for potential sale under the arrangement following the modification.
37

-- 37 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 6. Exhibits
Exhibit
Number 	Description of Exhibit
31.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
31.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
32.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.**
32.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.**
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL
document.
101.SCH 	XBRL Taxonomy Extension Schema Document.
101.CAL 	XBRL Taxonomy Calculation Linkbase Document.
101.DEF 	XBRL Taxonomy Definition Linkbase Document.
101.LAB 	XBRL Taxonomy Label Linkbase Document.
101.PRE 	XBRL Taxonomy Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to
long-term debt of the Registrant or its consolidated subsidiaries.
_______________________
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be
incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
38

-- 38 of 43 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: 	July 31, 2026 	THERMO FISHER SCIENTIFIC INC.
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer
/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer
39

-- 39 of 43 --

Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: July 31, 2026
/s/ Marc N. Casper
Marc N. Casper
Chairman and Chief Executive Officer

-- 40 of 43 --

Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James R. Meyer, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: July 31, 2026
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer

-- 41 of 43 --

Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 27, 2026 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman and Chief Executive Officer of the Company,
hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: July 31, 2026
/s/ Marc N. Casper
Marc N. Casper
Chairman and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 42 of 43 --

Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended June 27, 2026 as filed with the
Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James R. Meyer, Senior Vice President and Chief Financial Officer of the
Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: July 31, 2026
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 43 of 43 --